Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Oncolytics Biotech Inc. (ONCY : NSDQ)
 
 • Company Description   
Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most common family of genetic defects leading to cancer.

Number of Employees: 26

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.07 Daily Weekly Monthly
20 Day Moving Average: 92,440 shares
Shares Outstanding: 57.63 (millions)
Market Capitalization: $61.67 (millions)
Beta: 2.31
52 Week High: $3.21
52 Week Low: $1.04
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -20.74% -13.22%
12 Week -36.31% -28.42%
Year To Date -23.02% -5.96%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
804 322 - 11 AVENUE SW
-
CALGARY,A0 T2R 0C5
CAN
ph: 403-670-7377
fax: 403-283-0858
jpatton@oncolytics.ca http://www.oncolyticsbiotech.com
 
 • General Corporate Information   
Officers
Matthew C. Coffey - President and Chief Executive Officer and Director
Wayne Pisano - Chairman
Kirk J. Look - Chief Financial Officer
Deborah M. Brown - Director
Angela Holtham - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 682310875
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/05/22
Share - Related Items
Shares Outstanding: 57.63
Most Recent Split Date: 5.00 (0.11:1)
Beta: 2.31
Market Capitalization: $61.67 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.12 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.34 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.23
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 10.00%
vs. Previous Quarter: 18.18%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -66.47
12/31/21 - -61.94
09/30/21 - -70.06
ROA
03/31/22 - -53.50
12/31/21 - -50.38
09/30/21 - -56.36
Current Ratio
03/31/22 - 17.96
12/31/21 - 16.70
09/30/21 - 19.05
Quick Ratio
03/31/22 - 17.96
12/31/21 - 16.70
09/30/21 - 19.05
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 0.48
12/31/21 - 0.52
09/30/21 - 0.62
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©